Page last updated: 2024-09-04

varespladib and phenyl acetate

varespladib has been researched along with phenyl acetate in 53 studies

Compound Research Comparison

Studies (varespladib)	Trials (varespladib)	Recent Studies (post-2010) (varespladib)	Studies (phenyl acetate)	Trials (phenyl acetate)	Recent Studies (post-2010) (phenyl acetate)
80	11	49	41,232	1,558	8,330

Research

Studies (53)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (7.55)	18.2507
2000's	15 (28.30)	29.6817
2010's	20 (37.74)	24.3611
2020's	14 (26.42)	2.80

Authors

Authors	Studies
Armstrong, CT; Bach, NJ; Carlson, DG; Chang, CH; Dillard, RD; Draheim, SE; Fleisch, JH; Fox, N; Hartley, LW; Johnson, LM; Roehm, NW; Roman, CR; Smith, AC; Snyder, DW; Song, M	1
Hayakawa, T; Ishiguro, H; Kitagawa, M; Nakae, Y; Naruse, S; Ono, T; Yoshikawa, T	1
Chikazawa, Y; Furue, S; Hori, Y; Kuwabara, K; Maekawa, N; Matsukawa, A; Mikawa, K; Nishina, K; Obara, H; Ono, T; Shiga, M; Ueno, M; Yoshinaga, M	1
Mihelich, ED; Schevitz, RW	1
Hori, Y; Koike, K; Ono, T; Yamamoto, Y	1
Springer, DM	1
Furue, S; Hori, Y; Kuwabara, K; Matsukawa, A; Mikawa, K; Nishina, K; Obara, H; Ono, T; Shiga, M; Teshirogi, I; Tomita, Y; Ueno, M; Yoshinaga, M	1
Abraham, E; Bandi, V; Dmitrienko, A; Farid, N; Forgue, ST; Gervich, D; Jiang, F; Lowry, SF; Macias, W; Naum, C; Schein, RM; Skerjanec, S; Wunderink, R	1
Ajiki, T; Furue, S; Hori, Y; Kuwabara, K; Maruyama, T; Ono, T; Onoyama, H; Tanaka, K; Tomita, Y; Ueno, M; Yamada, K; Yamamoto, M	1
Bradley, JD; Dmitrienko, AA; Gluck, OS; Kivitz, AJ; Myers, SL; Sides, GD; Weaver, AL; Wiesenhutter, C	1
Bowton, DL; Dmitrienko, AA; Israel, E; Sides, GD; Zeiher, BG	1
Abraham, E; Dmitrienko, A; Fukiishi, Y; Laterre, PF; Steingrub, J; Zeiher, BG	1
Argüeso, P; Gipson, IK; Hori, Y; Russo, CL; Spurr-Michaud, SJ	1
Fraser, H; Lusis, AJ; Shaposhnik, Z; Trias, J; Wang, X	1
Chouinard, ML; Christie, RM; Eacho, PI; Fraser, H; Gould, KE; Hislop, C; Reidy, CA; Rick, HL; Trias, J	1
Fernandez, ML; Fraser, H; Leite, JO; Puglisi, M; Trias, J; Vaishnav, U	1
Garcia-Garcia, HM; Serruys, PW	1
Suckling, KE	1
Gelb, MH; Rosenson, RS	1
Suckling, K	1
Elliott, M; Goulder, M; Hislop, C; Rosenson, RS; Stasiv, Y; Waters, D	1
Cantor, WJ; Džavík, V; Horlick, EM; Ing, D; Lan, J; Lavi, S; Miner, SE; Osten, MD; Overgaard, CB; Plante, S; Robbins, K; Thorpe, K; Yip, PM	1
Rosenson, RS	1
Inazu, A	1
Capoluongo, E; Conti, G; De Luca, D; Minucci, A; Trias, J; Tripodi, D; Zuppi, C	1
Capoluongo, ED; Cogo, PE; Conti, G; De Luca, D; Gentile, L; Giardina, B; Marzano, L; Minucci, A; Piastra, M; Vendittelli, F	1
Antonelli, M; Capoluongo, ED; Conti, G; De Luca, D; Fraser, H; Gentile, L; Minucci, A; Perez-Gil, J; Trias, J; Vendittelli, F	1
Behrendt, M; Dikkers, A; Gautier, T; Grass, DS; Hurt-Camejo, E; Rader, DJ; Rosengren, B; Tietge, UJ	1
Bash, D; Brennan, DM; Cavender, MA; Jukema, JW; Kastelein, JJ; Koenig, W; Lincoff, AM; Menon, V; Nambi, V; Nicholls, SJ; Nissen, SE; Rosenson, RS; Schwartz, GG; Wright, RS	1
Corsini, A; Ferri, N	1
Holmes, MV; Talmud, PJ	1
Berry, E; Brglez, V; Cheong, C; Fernandez-Patron, C; Filep, JG; Hernandez-Anzaldo, S; Kassiri, Z; Lambeau, G; Lee, JS; Lehner, R; Leung, D; Yun, TJ	1
Bickler, P; Lewin, M; Merkel, J; Samuel, S	1
Brglez, V; Fernandez-Patron, C; Filep, JG; Hemmeryckx, B; Hernandez-Anzaldo, S; Kassiri, Z; Lambeau, G; Leung, D; Lijnen, RH; Vance, DE; Vance, JE	1
Kokotos, G; Kokotou, MG; Limnios, D; Nikolaou, A; Psarra, A	1
Huang, C; Wang, Y; Xiao, H; Xiong, S; Zhang, D; Zhang, J	1
Huang, C; Li, H; Li, Y; Sun, S; Xiao, H; Zhang, D	1
Kastelein, JJP; Lincoff, AM; Mani, P; Menon, V; Nicholls, SJ; Nissen, SE; Puri, R; Schwartz, GG; Shao, M	1
Bryan-Quirós, W; Fernández, J; Fontes, MRM; Gomes, AAS; Gutiérrez, JM; Lewin, MR; Lomonte, B; Salvador, GHM	1
Gutiérrez, JM; Lewin, MR; Lomonte, B; Williams, DJ	1
Coster, K; Fry, BG; Naude, A; Sundman, E; Walker, A; Youngman, NJ	1
Fontana Oliveira, IC; Gutiérrez, JM; Lewin, MR; Oshima-Franco, Y	1
Alagón, A; Bénard-Valle, M; Dashevsky, D; Frank, N; Fry, BG; Neri-Castro, E; Portes-Junior, JA; Youngman, NJ; Zdenek, CN	1
Chen, CK; Hsiao, YC; Hsieh, CH; Huang, GJ; Liaw, GW; Liu, CC; Liu, KL; Wu, CJ; Yang, YH	1
Borges, RJ; Fontes, MRM; Lewin, MR; Lomonte, B; Salvador, GHM	1
Fortes-Dias, CL; Garrido Cavalcante, WL; Gonçalves de Abreu, TA; Maciel, FV; Ortolani, PL; Ramos Pinto, ÊK; Valério Souza, NM	1
Carter, R; Chowdhury, A; Fry, BG; Lewin, MR; Zdenek, CN	1
Floriano, RS; Gaspar, MZ; Gerez, JR; Lobo, LGG; Lomonte, B; Quadros, LHB; Rogério, LM; Rowan, EG; Santarém, CL; Santos, NTS; Silva, EO; Silva, NJ; Silva-Carvalho, R; Zerbinatti, MC	1
Lingam, TMC; Tan, CH; Tan, KY	1
Floriano, RS; Gaspar, MZ; Gerez, JR; Giuffrida, R; Hyslop, S; Lobo, LGG; Lomonte, B; Quadros, LHB; Santarém, CL; Silva, EO; Silva, NJ; Silva-Carvalho, R	1
Cantuaria, NM; Cogo, JC; de Souza, J; Floriano, RS; Gutiérrez, JM; Hyslop, S; Oliveira, ICF; Oshima-Franco, Y; Silva Junior, NJ; Torres-Bonilla, KA; Yoshida, EH	1
Gao, D; Han, J; Hu, F; Wang, R; Yu, F; Yuan, H	1
Barvaliya, M; Biradar, P; Dodakallanavar, J; Harish, DR; Hiremath, K; Mahadevamurthy, RK; Patil, VS; Roy, S; Sampat, GH	1

Reviews

10 review(s) available for varespladib and phenyl acetate

Article	Year
Structure-based design of a new class of anti-inflammatory drugs: secretory phospholipase A(2) inhibitors, SPI. Biochimica et biophysica acta, 1999, Nov-23, Volume: 1441, Issue:2-3 Topics: Acetates; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Humans; Indoles; Keto Acids; Mice; Mice, Transgenic; Molecular Structure; Phospholipases A	1999
An update on inhibitors of human 14 kDa Type II s-PLA2 in development. Current pharmaceutical design, 2001, Volume: 7, Issue:3 Topics: Acetates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Drug Design; Group II Phospholipases A2; Humans; Indoles; Keto Acids; Molecular Structure; Patents as Topic; Phospholipases A; Phospholipases A2; Sulfonamides; Tretinoin	2001
Phospholipase A2 inhibitors. Current opinion in lipidology, 2009, Volume: 20, Issue:4 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetates; Animals; Atherosclerosis; Benzaldehydes; Blood Proteins; Humans; Indoles; Inflammation; Keto Acids; Oximes	2009
Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes. Current cardiology reports, 2009, Volume: 11, Issue:6 Topics: Acetates; Animals; Arteriosclerosis; Disease Progression; Humans; Indoles; Inflammation; Keto Acids; Lipoproteins; Mice; Oxidative Stress; Phospholipases A2, Secretory; Phospholipids	2009
Phospholipase A2s: developing drug targets for atherosclerosis. Atherosclerosis, 2010, Volume: 212, Issue:2 Topics: Acetates; Animals; Atherosclerosis; Benzaldehydes; Biomarkers; Cytosol; Drug Design; Enzyme Inhibitors; Humans; Indoles; Keto Acids; Lipoproteins; Mice; Oximes; Phospholipase A2 Inhibitors; Phospholipases A2	2010
[Novel therapy for atherosclerosis and inflammatory vascular disease]. Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69, Issue:1 Topics: Acetates; Amides; Apolipoprotein A-I; Atherosclerosis; Benzaldehydes; Blood Proteins; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Drug Design; Esters; Humans; Indoles; Keto Acids; Molecular Targeted Therapy; Oxazolidinones; Oximes; Probucol; Quinazolines; Quinazolinones; Sulfhydryl Compounds	2011
[Role of secreted and lipoprotein-associated phospholipase A2 in cardiovascular risk]. Giornale italiano di cardiologia (2006), 2014, Volume: 15, Issue:12 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetates; Acute Coronary Syndrome; Atherosclerosis; Benzaldehydes; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Humans; Indoles; Keto Acids; Lipoproteins; Oximes; Phospholipase A2 Inhibitors; Phospholipases A	2014
Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart Disease. Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:11 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetates; Animals; Benzaldehydes; Biomarkers; Coronary Disease; Humans; Indoles; Keto Acids; Molecular Targeted Therapy; Oximes; Phospholipase A2 Inhibitors; Phospholipases A2, Secretory; Signal Transduction; Treatment Outcome	2015
Inhibitors of phospholipase A Expert opinion on therapeutic patents, 2017, Volume: 27, Issue:2 Topics: Acetates; Animals; Benzaldehydes; Biomarkers; Cardiovascular Diseases; Drug Design; Humans; Indoles; Inflammation; Keto Acids; Oximes; Patents as Topic; Phospholipase A2 Inhibitors	2017
Unraveling snake venom phospholipase A Pharmacological reports : PR, 2023, Volume: 75, Issue:6 Topics: Acetates; Animals; Horses; Humans; Inflammation; Phospholipases A2; Sheep; Snake Bites; Snake Venoms	2023

Trials

9 trial(s) available for varespladib and phenyl acetate

Article	Year
Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Critical care medicine, 2003, Volume: 31, Issue:3 Topics: Acetates; Aged; Cause of Death; Critical Illness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Female; Group II Phospholipases A2; Hospital Mortality; Humans; Indoles; Inflammation; Infusions, Intravenous; Keto Acids; Male; Middle Aged; Molecular Weight; Multiple Organ Failure; Phospholipases A; Phospholipases A2; Proportional Hazards Models; Prospective Studies; Safety; Survival Analysis; Systemic Inflammatory Response Syndrome; Time Factors; Treatment Outcome; United States	2003
A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. The Journal of rheumatology, 2005, Volume: 32, Issue:3 Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Indoles; Keto Acids; Middle Aged; Phospholipases A; Phospholipases A2; Placebos	2005
Impact of a soluble phospholipase A2 inhibitor on inhaled allergen challenge in subjects with asthma. The Journal of asthma : official journal of the Association for the Care of Asthma, 2005, Volume: 42, Issue:1 Topics: Acetates; Administration, Inhalation; Adult; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Indoles; Keto Acids; Male; Phospholipases A; Phospholipases A2; Skin Tests	2005
LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis. Critical care medicine, 2005, Volume: 33, Issue:8 Topics: Acetates; Double-Blind Method; Europe; Female; Group II Phospholipases A2; Humans; Indoles; Infusions, Intravenous; Keto Acids; Male; Middle Aged; Multiple Organ Failure; Phospholipases A; Phospholipases A2; Risk; Sepsis; United States	2005
Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. Journal of the American College of Cardiology, 2010, Sep-28, Volume: 56, Issue:14 Topics: Acetates; Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Indoles; Keto Acids; Logistic Models; Male; Middle Aged; Phospholipases A2, Secretory; Prospective Studies; Pyrroles; Reference Values; Treatment Outcome	2010
The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial. Circulation, 2010, Dec-07, Volume: 122, Issue:23 Topics: Acetates; Acute Coronary Syndrome; Aged; Angioplasty; Biomarkers; Enzyme Inhibitors; Female; Humans; Indoles; Keto Acids; Male; Middle Aged; Phospholipases A2, Secretory	2010
After FRANCIS: next steps in the clinical evaluation of varespladib methyl. Future cardiology, 2011, Volume: 7, Issue:1 Topics: Acetates; Acute Coronary Syndrome; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Keto Acids; Logistic Models; Male; Middle Aged; Phospholipases A2, Secretory; Pyrroles	2011
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA, 2014, Jan-15, Volume: 311, Issue:3 Topics: Acetates; Acute Coronary Syndrome; Aged; Angina, Unstable; Atherosclerosis; Atorvastatin; Double-Blind Method; Early Termination of Clinical Trials; Female; Heptanoic Acids; Humans; Indoles; Keto Acids; Male; Middle Aged; Myocardial Infarction; Phospholipases A; Phospholipases A2, Secretory; Pyrroles; Risk; Stroke; Survival Analysis; Treatment Outcome	2014
Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial. JAMA cardiology, 2019, 04-01, Volume: 4, Issue:4 Topics: Acetates; Acute Coronary Syndrome; Aged; Angina, Unstable; Australia; C-Reactive Protein; Death; Europe; Female; Humans; India; Indoles; Keto Acids; Male; Middle Aged; Myocardial Infarction; New Zealand; North America; Phospholipase A2 Inhibitors; Placebos; Risk Factors; Stroke; Treatment Outcome	2019

Other Studies

34 other study(ies) available for varespladib and phenyl acetate

Article	Year
Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI. The Journal of pharmacology and experimental therapeutics, 1999, Volume: 288, Issue:3 Topics: Acetates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Cell Line; Cloning, Molecular; Cricetinae; Group II Phospholipases A2; Guinea Pigs; Humans; Indoles; Keto Acids; Male; Mesocricetus; Mice; Mice, Transgenic; Muscle, Smooth; Phospholipases A; Phospholipases A2; Pleura; Rabbits; Rats; Recombinant Proteins; Thromboxane A2	1999
Effect of a new inhibitor of type II phospholipase A2 on experimental acute pancreatitis in rats. Pancreas, 1999, Volume: 19, Issue:2 Topics: Acetates; Acute Disease; Animals; Enzyme Inhibitors; Hemorrhage; Indoles; Keto Acids; Male; Pancreas; Pancreatitis; Phospholipases A; Phospholipases A2; Rats; Rats, Wistar; Survival Rate; Taurocholic Acid; Trypsin	1999
Crucial role of group IIA phospholipase A(2) in oleic acid-induced acute lung injury in rabbits. American journal of respiratory and critical care medicine, 1999, Volume: 160, Issue:4 Topics: Acetates; Animals; Bronchoalveolar Lavage Fluid; Capillary Permeability; Dose-Response Relationship, Drug; Enzyme Inhibitors; Extravascular Lung Water; Group II Phospholipases A2; Indoles; Interleukin-8; Keto Acids; Leukotriene B4; Lung; Lung Compliance; Male; Oleic Acid; Oxygen; Phospholipases A; Phospholipids; Pulmonary Edema; Rabbits; Respiratory Distress Syndrome; Thromboxane A2	1999
Group IIA phospholipase A2 mediates lung injury in intestinal ischemia-reperfusion. Annals of surgery, 2000, Volume: 232, Issue:1 Topics: Acetates; Animals; Disease Models, Animal; Humans; Indoles; Intestines; Keto Acids; Liver; Lung; Male; Phospholipases A; Phospholipases A2; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Respiratory Distress Syndrome	2000
Therapeutic time-window of a group IIA phospholipase A2 inhibitor in rabbit acute lung injury: correlation with lung surfactant protection. Critical care medicine, 2001, Volume: 29, Issue:4 Topics: Acetates; Animals; Blood Gas Analysis; Bronchoalveolar Lavage Fluid; Enzyme Inhibitors; Group II Phospholipases A2; Indoles; Keto Acids; Male; Oleic Acid; Phospholipases A; Phospholipases A2; Pulmonary Surfactants; Rabbits; Respiratory Distress Syndrome	2001
Effect of a selective inhibitor of secretory phospholipase A2, S-5920/LY315920Na, on experimental acute pancreatitis in rats. Journal of pharmacological sciences, 2004, Volume: 96, Issue:2 Topics: Acetates; Acute Disease; Animals; Dose-Response Relationship, Drug; Group IB Phospholipases A2; In Vitro Techniques; Indoles; Keto Acids; Male; Pancreatitis; Phospholipases A; Phospholipases A2; Rats; Rats, Wistar	2004
Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Investigative ophthalmology & visual science, 2005, Volume: 46, Issue:11 Topics: Acetates; Aristolochic Acids; Blotting, Western; CA-125 Antigen; Cell Line; Conjunctiva; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Epithelial Cells; Epithelium; Gene Expression Profiling; Gene Expression Regulation; Humans; Indoles; Keto Acids; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Phospholipases A; Phospholipases A2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tretinoin; Up-Regulation	2005
The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). Journal of lipid research, 2009, Volume: 50, Issue:4 Topics: Acetates; Animals; Apolipoproteins E; Aryldialkylphosphatase; Atherosclerosis; Drug Synergism; Enzyme Inhibitors; Indoles; Keto Acids; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Phospholipases A2, Secretory; Pravastatin; Prodrugs	2009
Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice. Journal of cardiovascular pharmacology, 2009, Volume: 53, Issue:1 Topics: Acetates; Aneurysm; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Atherosclerosis; Blood Proteins; Cholesterol; Group II Phospholipases A2; Humans; Indoles; Keto Acids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Phospholipases A2, Secretory	2009
A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs. BMC cardiovascular disorders, 2009, Feb-17, Volume: 9 Topics: Acetates; Animals; Aorta, Thoracic; Atherosclerosis; Blood Proteins; Cholesterol; Diet, Atherogenic; Granulocyte-Macrophage Colony-Stimulating Factor; Guinea Pigs; Indoles; Interleukin-10; Interleukin-12; Keto Acids; Lipid Metabolism; Magnetic Resonance Imaging; Phospholipase A2 Inhibitors	2009
Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic. Expert opinion on investigational drugs, 2009, Volume: 18, Issue:10 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetates; Animals; Atherosclerosis; Benzaldehydes; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Indoles; Keto Acids; Oximes; Phospholipase A2 Inhibitors	2009
Varespladib inhibits secretory phospholipase A2 in bronchoalveolar lavage of different types of neonatal lung injury. Journal of clinical pharmacology, 2012, Volume: 52, Issue:5 Topics: Acetates; Albumins; Bronchoalveolar Lavage Fluid; Enzyme Inhibitors; Female; Gestational Age; Humans; Hyaline Membrane Disease; Indoles; Infant, Newborn; Italy; Keto Acids; Lung Injury; Male; Meconium Aspiration Syndrome; Pancreas; Phospholipases A2, Secretory; Respiratory Distress Syndrome, Newborn; Respiratory Tract Infections	2012
Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDS. PloS one, 2012, Volume: 7, Issue:10 Topics: Acetates; Bronchoalveolar Lavage Fluid; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Indoles; Infant; Infant, Newborn; Keto Acids; Phospholipases A2, Secretory; Respiratory Distress Syndrome, Newborn	2012
Surfactant and varespladib co-administration in stimulated rat alveolar macrophages culture. Current pharmaceutical biotechnology, 2013, Volume: 14, Issue:4 Topics: Acetates; Acute Lung Injury; Animals; Cells, Cultured; Disease Models, Animal; Fatty Acids, Nonesterified; Indoles; Keto Acids; Macrophages, Alveolar; Phospholipases A2, Secretory; Pulmonary Surfactants; Rats; Tumor Necrosis Factor-alpha	2013
Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice. Arteriosclerosis, thrombosis, and vascular biology, 2013, Volume: 33, Issue:12 Topics: Acetates; Animals; Aorta; Aortic Diseases; Apolipoprotein E3; Apolipoproteins B; Atherosclerosis; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Enzyme Inhibitors; Female; Group II Phospholipases A2; Humans; Hypercholesterolemia; Indoles; Keto Acids; Lipoproteins, VLDL; Liver; Mice; Mice, Inbred C57BL; Mice, Transgenic; Plaque, Atherosclerotic	2013
Identification of a Novel Heart-Liver Axis: Matrix Metalloproteinase-2 Negatively Regulates Cardiac Secreted Phospholipase A2 to Modulate Lipid Metabolism and Inflammation in the Liver. Journal of the American Heart Association, 2015, Nov-13, Volume: 4, Issue:11 Topics: Acetates; Animals; Antibodies; Cells, Cultured; Chemokine CCL7; Cholesterol, Dietary; Enzyme Inhibitors; Gene Expression Regulation; Genetic Predisposition to Disease; Hepatitis; Indoles; Keto Acids; Lipid Metabolism; Liver; Matrix Metalloproteinase 2; Mice, Inbred C57BL; Mice, Knockout; Myocytes, Cardiac; Phenotype; Phospholipases A2, Secretory; Signal Transduction; Time Factors; Transcription, Genetic; Triglycerides	2015
Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation. Toxins, 2016, 08-25, Volume: 8, Issue:9 Topics: Acetates; Animals; Antidotes; Disease Models, Animal; Dose-Response Relationship, Drug; Elapid Venoms; Indoles; Keto Acids; Mice; Phospholipase A2 Inhibitors; Phospholipases A2; Prodrugs; Rats, Sprague-Dawley; Reptilian Proteins; Snake Bites; Time Factors; Viper Venoms	2016
Novel Role for Matrix Metalloproteinase 9 in Modulation of Cholesterol Metabolism. Journal of the American Heart Association, 2016, 09-30, Volume: 5, Issue:10 Topics: Acetates; Animals; Cholestanetriol 26-Monooxygenase; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Gene Expression Regulation; Indoles; Intestinal Absorption; Keto Acids; Lipid Metabolism; Liver; Male; Matrix Metalloproteinase 9; Mice; Mice, Knockout; Phospholipase A2 Inhibitors; Phospholipases A2; Sterol Regulatory Element Binding Protein 2	2016
Exploration of the Inhibitory Potential of Varespladib for Snakebite Envenomation. Molecules (Basel, Switzerland), 2018, Feb-12, Volume: 23, Issue:2 Topics: Acetates; Alanine Transaminase; Animals; Antivenins; Aspartate Aminotransferases; Creatine Kinase; Crotalid Venoms; Crotalinae; Ecchymosis; Edema; Female; Indoles; Isoenzymes; Keto Acids; L-Lactate Dehydrogenase; Mice; Muscle, Skeletal; Phospholipase A2 Inhibitors; Phospholipases A2; Snake Bites	2018
Inactivation of Venom PLA₂ Alleviates Myonecrosis and Facilitates Muscle Regeneration in Envenomed Mice: A Time Course Observation. Molecules (Basel, Switzerland), 2018, Jul-31, Volume: 23, Issue:8 Topics: Acetates; Angiopoietins; Animals; Antidotes; Crotalid Venoms; Crotalinae; Gene Expression Regulation; Hemorrhage; Indoles; Keto Acids; Male; Mice; Muscle, Skeletal; MyoD Protein; Myogenin; Necrosis; Nerve Growth Factor; Phospholipases A2, Cytosolic; Recovery of Function; Snake Bites; Ulcer	2018
Structural basis for phospholipase A Scientific reports, 2019, 11-20, Volume: 9, Issue:1 Topics: Acetates; Animals; Bothrops; Crystallography, X-Ray; Indoles; Keto Acids; Molecular Dynamics Simulation; Phospholipase A2 Inhibitors; Phospholipases A2; Protein Conformation; Reptilian Proteins; Toxins, Biological	2019
Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms. Toxins, 2020, 02-20, Volume: 12, Issue:2 Topics: Acetates; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Indoles; Keto Acids; Lethal Dose 50; Mice; Neurotoxicity Syndromes; Phospholipase A2 Inhibitors; Phospholipases A2; Snake Bites; Snake Venoms; Survival Analysis; Time Factors	2020
Varespladib (LY315920) neutralises phospholipase A Comparative biochemistry and physiology. Toxicology & pharmacology : CBP, 2020, Volume: 236 Topics: Acetates; Animals; Antivenins; Blood Coagulation; Factor V; Factor Xa; Humans; Indoles; Keto Acids; Phospholipase A2 Inhibitors; Phospholipases A2; Snake Venoms; Viperidae	2020
Varespladib (LY315920) inhibits neuromuscular blockade induced by Oxyuranus scutellatus venom in a nerve-muscle preparation. Toxicon : official journal of the International Society on Toxinology, 2020, Volume: 187 Topics: Acetates; Antivenins; Elapid Venoms; Indoles; Keto Acids; Neuromuscular Blockade; Neuromuscular Diseases; Neuromuscular Junction; Neurotoxicity Syndromes; Neurotoxins; Snake Bites	2020
Anticoagulant Micrurus venoms: Targets and neutralization. Toxicology letters, 2021, Feb-01, Volume: 337 Topics: Acetates; Animals; Anticoagulants; Blood Coagulation; Coral Snakes; Elapid Venoms; Humans; Indoles; Keto Acids; Mice; Phospholipase A2 Inhibitors; Receptors, Phospholipase A2; Snake Bites; Species Specificity; Thromboplastin; Whole Blood Coagulation Time	2021
Snake venom proteome of Protobothrops mucrosquamatus in Taiwan: Delaying venom-induced lethality in a rodent model by inhibition of phospholipase A Journal of proteomics, 2021, 03-15, Volume: 234 Topics: Acetates; Animals; Antivenins; Chromatography, Liquid; Indoles; Keto Acids; Mice; Phospholipases A2; Proteome; Proteomics; Rodentia; Snake Venoms; Taiwan; Tandem Mass Spectrometry; Trimeresurus	2021
The synthetic varespladib molecule is a multi-functional inhibitor for PLA Biochimica et biophysica acta. General subjects, 2021, Volume: 1865, Issue:7 Topics: Acetates; Animals; Bothrops; Crystallography, X-Ray; Group II Phospholipases A2; Indoles; Keto Acids; Mice; Muscle Fibers, Skeletal; Phospholipase A2 Inhibitors; Phospholipases A2; Reptilian Proteins	2021
Varespladib (LY315920) prevents neuromuscular blockage and myotoxicity induced by crotoxin on mouse neuromuscular preparations. Toxicon : official journal of the International Society on Toxinology, 2021, Oct-30, Volume: 202 Topics: Acetates; Animals; Crotalid Venoms; Crotoxin; Indoles; Keto Acids; Mice; Myotoxicity	2021
The Relative Efficacy of Chemically Diverse Small-Molecule Enzyme-Inhibitors Against Anticoagulant Activities of African Spitting Cobra ( Frontiers in immunology, 2021, Volume: 12 Topics: Acetates; Africa; Animals; Antivenins; Enzyme Inhibitors; Hydroxamic Acids; In Vitro Techniques; Indoles; Keto Acids; Naja; Organic Chemicals; Snake Bites; Snake Venoms	2021
In vivo treatment with varespladib, a phospholipase A Toxicology letters, 2022, Mar-01, Volume: 356 Topics: Acetates; Animals; Biomarkers; Blood Coagulation Disorders; Coral Snakes; Elapid Venoms; Gene Expression Regulation, Enzymologic; Indoles; Keto Acids; L-Lactate Dehydrogenase; Neuroprotective Agents; Phospholipase A2 Inhibitors; Phospholipases A2; Rats; Rats, Wistar	2022
Varespladib (LY315920) rescued mice from fatal neurotoxicity caused by venoms of five major Asiatic kraits (Bungarus spp.) in an experimental envenoming and rescue model. Acta tropica, 2022, Volume: 227 Topics: Acetates; Animals; Antivenins; Bungarotoxins; Bungarus; Elapid Venoms; Indoles; Keto Acids; Mice; Snake Bites	2022
Partial efficacy of a Brazilian coralsnake antivenom and varespladib in neutralizing distinct toxic effects induced by sublethal Micrurus dumerilii carinicauda envenoming in rats. Toxicon : official journal of the International Society on Toxinology, 2022, Jul-15, Volume: 213 Topics: Acetates; Animals; Antivenins; Brazil; Coral Snakes; Elapid Venoms; Indoles; Keto Acids; Rats	2022
Effect of the phospholipase A Toxicon : official journal of the International Society on Toxinology, 2022, Jul-30, Volume: 214 Topics: Acetates; Animals; Antivenins; Crotalid Venoms; Crotoxin; Drug Synergism; Indoles; Keto Acids; Mice; Neuromuscular Blockade; Neuromuscular Diseases; Phospholipases A2	2022
Phospholipase A Toxicon : official journal of the International Society on Toxinology, 2022, Volume: 215 Topics: Acetates; Acute Kidney Injury; Animals; Indoles; Insect Bites and Stings; Keto Acids; Phospholipases A2; Rats; Wasp Venoms; Wasps	2022